Invasive aspergillosis: Current and future challenges in diagnosis and therapy

Clinical Microbiology and Infection

Volumn 10, Issue 1, 2004, Pages 2-4

  Hope, W W ^a   Denning, D W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Amphotericin; Aspergillosis; Diagnosis; Therapy; Voriconazole

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ASTEMIZOLE; CISAPRIDE; CYCLOSPORIN; CYTOCHROME P450 2C19; ITRACONAZOLE; RAPAMYCIN; TACROLIMUS; TERFENADINE; VORICONAZOLE; WARFARIN;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TARGETING; EDITORIAL; HUMAN; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL;

ASPERGILLUS;

EID: 1642545694     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.00809.x     Document Type: Editorial

References (11)

1. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
2. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608-615.
3. Blot F, Ede C, Nitenberg GM. Voriconazole versus amphotericin B for invasive aspergillosis. N Engl J Med 2002; 347: 2080.
4. Anonymous. Briefing document for voriconazole for the antiviral drug products advisory committee meeting. http://www.fda.gov/ohrms/dockets/ac/01/briefing/ 3792b2-02_FDA-voriconazole.pdf. 2001.
5. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003; 31: 540-547.
6. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-637.
7. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998; 42: 741-745.
8. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000; 46: 229-234.
9. Warris A, Weemaes CM, Verweij PE. Multidrug resistance in Aspergillus fumigatus. N Engl J Med 2002; 347: 2173-2174.
10. Lewis RE, Prince RA, Chi J, Kontoyiannis DP. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2002; 46: 3208-3214.
11. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.